|By Marketwired .||
|July 23, 2014 07:00 AM EDT||
LAS VEGAS, NV--(Marketwired - July 23, 2014) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, announced the receipt of its first 3 sample batches of High Grade CBD (Cannabidiol)Rich Industrial Hemp-based Oil that can be distributed in all 50 states and 40 countries as a nutritional and dietary supplement. ETST has confirmed test results showing its High Grade CBD (Cannabidiol) Rich Hemp Oil is specifically targeted for the nutritional and dietary supplement markets having top quality control which has been tested for microbiological screening, chemical residue screening and cannabinoid profiling. More importantly, with this specific type of High Grade CBD (Cannabidiol) Rich Hemp Oil, ETST now looks to have a significant cost advantage and ability to scale in the CBD arena as a leading provider, wholesaler and third-party distribution company for High Grade CBD (Cannabidiol)Rich Hemp Oil.
ETST welcomes and invites all interested parties to contact the company directly at [email protected] in regards to securing its High Grade CBD (Cannabidiol)Rich Hemp Oil. Furthermore ETST is also open to forming new strategic partnerships, joint ventures and or supplying third party resellers it's High Grade CBD (Cannabidiol)Rich Hemp Oil at Wholesale prices in order to better help supply the health and wellness markets on a large scale. The company feels it can grow at a much faster pace by focusing on becoming a large whole distributor of its High Grade CBD (Cannabidiol)Rich Hemp Oil by aligning itself with key strategic partners and third party resellers that are already well diversified in the nutritional and dietary supplement markets.
Harvey Katz PhD, CEO of ETST stated, "As an emerging nutritional and dietary supplement hemp wellness company, ETST is looking forward to working with new strategic partners, vendors and third party resellers to help them create, develop and manufacture innovative products designed to promote health and wellness benefits by utilizing its High Grade CBD (Cannabidiol) Rich Hemp Oil."
ETST mission is to educate the public on the health benefits of CBD (Cannabidiol)Rich Hemp Oil, to help optimize purity and formulations, and to find new product delivery systems. ETST looks to educate consumers on the numerous nutritional benefits of CBD and industrial hemp. ETST is working with industry nutritional and dietary supplement experts in order to spearhead consumer health and wellness education as well as product development for the CBD Hemp based rich oil.
ETST feels there is a lot of misconception in the marketplace right now in regards to the proper dosing and percentage of CBD (Cannabidiol) Rich Hemp Oil needed to take as a nutritional and dietary supplement as well as for overall wellness. This also includes the amount needed to help with certain health disorders and conditions.
ETST plans on developing certain guidelines for the correct amount of dosing of High Grade CBD (Cannabidiol) Rich Hemp Oil as a nutritional and dietary supplement to be used for various disorders and conditions through upcoming clinical trials. One of the main differences between ETST and the prominent NASDAQ-traded GW Pharmaceuticals plc GW Pharma is that ETST is focused on certain High Grade CBD (Cannabidiol)Rich Hemp Oil that is considered to be "food based" and therefore legal in all 50 states and more than 40 countries. Cannabinoids (cannabidiol/CBD) are natural constituents of the hemp plant, and CBD is derived from hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD in hemp is providing overwhelming evidence of significant health and wellness benefits. CBD possesses no psychoactive properties and therefore is a ready for market hemp based ingredient. According to scientific and clinical studies, CBD has the potential to help a range of conditions, including epilepsy, diabetes, rheumatoid arthritis, chronic pain, alcoholism, schizophrenia, PTSD, antibiotic-resistant infections, and various neurological disorders (Source: National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov). CBD has demonstrated neurogenic and neuroprotective effects and its anti-cancer properties are currently being investigated at several academic research centers in the United States and abroad.
The Food and Drug Administration (FDA) currently considers hemp based Cannabinoids, including CBD, to be "food based" and therefore legal. These new non-psychoactive CBD-rich hemp oil products that ETST will look to market and distribute are legal and available to consumers in all fifty states and in more than forty countries. CBD (Cannabidiol), a naturally-occurring constituent of the industrial hemp plant, promotes and supports the nutritional health of aging bodies. Source: US Government patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants."
ABOUT ETST: ETST is a unique biotechnology company focused on delivering cutting edge nutraceuticals, bioceuticals and dietary supplements designed to excel in industries such as health, wellness, sports and alternative medicine to improve the quality of life for consumers worldwide. ETST is also dedicated in providing natural alternatives to prescription medications such as nutritional supplements and dietary supplements that help improve common disorders and illnesses. This may include products such as vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods, CBD (Cannabidiol) as a natural constituent of hemp oil and other products. These products will be in various formulations and delivery forms including but not limited to capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
ETST has an exclusive distribution agreement with Cromogen Biotechnologies ("Cromogen") focusing on the purchase of raw hemp-based CBD (Cannabidiol) rich oil. ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. Cromogen applies a decade of research and development in plant science and phytocannabinoid studies to the manufacturing of cannabidiol-rich hemp foods and ingredients. The technology currently in place allows for the processing of 5 metric tons of hemp fiber per day, which can isolate trace amounts of phytocannabinoids as low as 300 parts per million. Common quality control concerns in the phytocannabinoid industry have been mitigated by Cromogen's R&D team through leveraging pharmaceutical processes and technology for hemp food and oil production. For more information on Cromogen visit: http://www.cromogenbiotechnology.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.
Aug. 29, 2016 07:45 PM EDT Reads: 1,653
Aug. 29, 2016 07:00 PM EDT Reads: 1,975
Aug. 29, 2016 06:45 PM EDT Reads: 814
Aug. 29, 2016 06:15 PM EDT Reads: 284
Aug. 29, 2016 06:15 PM EDT Reads: 780
Aug. 29, 2016 05:03 PM EDT Reads: 219
Aug. 29, 2016 04:30 PM EDT Reads: 3,561
Aug. 29, 2016 02:15 PM EDT Reads: 3,739
Aug. 29, 2016 02:00 PM EDT Reads: 988
Aug. 29, 2016 02:00 PM EDT Reads: 2,480
Aug. 29, 2016 12:45 PM EDT Reads: 2,024
Aug. 29, 2016 12:15 PM EDT Reads: 825
Aug. 29, 2016 12:00 PM EDT Reads: 880
Aug. 29, 2016 12:00 PM EDT Reads: 3,194
Aug. 29, 2016 12:00 PM EDT Reads: 828